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Acute asthma attacks (asthma exacerbations) are increasing episodes of shortness of breath, cough, wheezing or chest tightness associated 
with a decrease in airflow that can be quantified and monitored by measurement of lung function (peak expiratory flow (PEF) or forced 
expiratory volume in the 1st second) and requiring emergency room treatment or admission to hospital for acute asthma and/or systemic 
glucocorticosteroids for management. The goals of treatment are to relieve hypoxaemia and airflow obstruction as quickly as possible, 
restore lung function, and provide a suitable plan to avoid relapse. Severe exacerbations are potentially life-threatening and their treatment 
requires baseline assessment of severity, close monitoring, and frequent reassessment using objective measures of lung function (PEF) 
and oxygen saturation. Patients at high risk of asthma-related death require particular attention. First-line therapy consists of oxygen 
supplementation, repeated administration of inhaled short-acting bronchodilators (beta-2-agonists and ipratropium bromide), and 
early systemic glucocorticosteroids. Intravenous magnesium sulphate and aminophylline are second- and third-line treatment strategies, 
respectively, for poorly responding patients. Intensive care is indicated for severe asthma that is not responsive to first-line treatment. 
Antibiotics are only indicated when there are definite features of bacterial infection. Factors that precipitated the acute asthma episode 
should be identified and preventive measures implemented. Acute asthma is preventable with optimal control of chronic asthma.
S Afr Med J 2013;103(3):189-198. DOI:10.7196/SAMJ.6526
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1. Introduction
The prevalence of asthma is increasing worldwide,[1] and surveys 
indicate that the majority of patients in developed and developing 
countries do not receive optimal care and are therefore not well 
controlled.[1] The aim of this guideline is to promote an optimal 
standard of management of acute asthma in order to facilitate rapid 
recovery and transition to chronic care. It is intended as a companion 
to the management of chronic persistent asthma, as adherence to the 
latter plays a pivotal role in reducing acute asthma morbidity and 
mortality.
2. Methodology
The South African Thoracic Society first published a guideline for 
the management of acute asthma in 1994. This 2013 update of the 
guideline was prompted by the need for:
• incorporation of advances in the pharmacological treatment of 
acute severe asthma
• early recognition and objective assessment of acute severe asthma
• optimal management and rapid transition to chronic care
• prevention of acute attacks
• harmonisation with international guidelines (e.g. Global 
Initiative for Asthma (GINA)).
The guideline was developed following meetings with a working 
group of pulmonologists and primary care/family medicine 
practitioners constituted by the South African Thoracic Society 
and chaired by Professor U G Lalloo. The initial meeting was 
held with the working group on 2 - 3 July 2005. Subsequently 
the editorial board was convened and met on several further 
occasions to develop and finalise this guideline document. The 
meetings were sponsored by the National Asthma Education 
Program (NAEP) of the South African Thoracic Society. This 
was made possible through unrestricted educational grants to 
the NAEP from the SA Thoracic Society, Altana Madaus (now 
Nycomed), AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline 
and MSD.
3. Evidence
The strategies recommended in this guideline are classified according 
to the evidence categories in Table 1 and denoted as evidence A, B, 
C and D.
4. Acute asthma symptoms, acute 
asthma and exacerbations
The cardinal symptoms of asthma are cough, tightness of chest, 
wheeze and shortness of breath. There is remarkable variation in the 
perception of asthma symptoms and therefore concern for patients 
who have a blunted perception of the severity of their asthma 
symptoms.[1]
Acute symptoms are episodic and are managed by self-medication 
with a reliever medication (inhalation of beta-2 (β2)-agonists). The 
frequent use of reliever medication indicates suboptimal control and 
demands attention to controller treatment.[1]
Asthma exacerbations, also referred to as acute asthma or 
asthma attacks, result from frequent and progressive asthma 
symptoms and require early recognition to prevent morbidity and 
mortality. In some patients acute exacerbations may be of abrupt 
onset and progress rapidly to respiratory failure and death. An 
asthma exacerbation may be defined for practical purposes as a 
progressive (usually) or abrupt worsening in asthma symptoms, 
with increased use of bronchodilators (rescue medication) with 
progressively decreasing response and/or a decrease in pulmonary 
function as measured by PEF or spirometry.[1,2] The term status 
asthmaticus is used less often and refers to an asthma exacerbation 
that is severe and continuous.
The features of acute asthma are due to widespread narrowing of 
the airways. The pathophysiology of airway narrowing is complex, 
and smooth-muscle constriction, hypersecretion of mucus and 
mucus plugging of small airways, oedema of the airway wall 
with infiltration with inflammatory cells (e.g. neutrophils and 
eosinophils), and disruption of the airway epithelium are all 
involved.[1]
5. Management of acute asthma
The management of acute asthma is summarised in Fig. 1. The key 
steps are:
5.1 Initial assessment and classification of severity
A brief history and physical examination should be conducted 
immediately the patient presents and at the same time as treatment 
is initiated.[1] A detailed history may follow once the patient is 
stable and should include the duration and severity of symptoms, 
exercise tolerance, sleep disturbance, all current medications 
(including devices and doses prescribed and taken, time of onset 
and cause of the present attack, possible triggers, and presence of 
high-risk factors (see below)). The examination should assess the 
Table 1. Categories of evidence for management strategies in 
asthma (reproduced with permission from Global Initiative 
for Asthma 2006)
Evidence 
category Sources of evidence 
A Randomised controlled trials: Rich body of data 
B Randomised controlled trials: Limited body of data 
C Non-randomised trials: Observational studies
D Panel consensus judgement 
Key points
• Acute asthma attacks (asthma exacerbations) are episodes of 
increased shortness of breath, coughing, wheezing or chest 
tightness associated with a decrease in airflow that can be 
quantified and monitored by measurement of lung function 
(peak expiratory flow (PEF) or forced expiratory volume in 
the 1st second (FEV1)) and require emergency room treatment 
or admission to hospital for acute asthma, and/or systemic 
glucocorticosteroids (CS) for management.
• The goals of treatment are to relieve hypoxaemia and airflow 
obstruction as quickly as possible, restore lung function, and 
provide a suitable plan to avoid relapse.
• Severe exacerbations are potentially life-threatening, and 
their treatment requires baseline assessment of severity, 
close monitoring, and frequent reassessment using objective 
measures of lung function (PEF) and oxygen saturation.
• Patients at high risk of asthma-related death require particular 
attention.
• First-line therapy consists of oxygen supplementation, repeated 
administration of inhaled short-acting bronchodilators (beta-
2-agonists and ipratropium bromide), and early systemic CS.
• The factors that precipitated the attack should be identified and 
attempts made to prevent future attacks.
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presence of any complications (e.g. pneumonia, lobar collapse or 
atelectasis, pneumothorax and pneumomediastinum). Objective 
functional assessments such as baseline PEF or FEV1 and arterial 
oxygen saturation (SpO2) measurements (by pulse oximetry) 
before starting treatment should be routine[1,3-7] (evidence C). PEF 
measurement is preferred in emergency units, hospital wards, 
primary care clinics and general practitioner surgeries because 
it is widely available, simple, inexpensive, portable and safe. A 
baseline PEF measurement should be made before treatment is 
initiated[1] (see Appendix I, ‘How to measure peak expiratory flow 
(PEF)’), but may not be possible in patients with severe respiratory 
distress. Arterial blood gas measurements are required if the SpO2 
is <92% or the attack is responding poorly to treatment.[6,7] The 
measurement should be made while the patient is on supplemental 
oxygen. A chest radiograph is not routine but should be done if 
a complication or other disease (e.g. tuberculosis, lung cancer) 
is suspected or if there is poor response to treatment, but 
its acquisition must not compromise ongoing monitoring and 
treatment.[8]
Acute asthma may be conveniently classified as mild, moderate 
or severe (life-threatening) based on symptoms, signs, and lung 
function and laboratory data. Table 2 summarises the features 
of acute asthma and criteria used to classify the severity of acute 
asthma.
5.2 Identification of patients at high risk
In addition to patients who are classified as having acute severe 
asthma, patients must also be considered as at high risk if they have 
any of the features listed in Table 3.[9,10] Such patients are at risk of 
rapid deterioration.
5.3 Treatment
The goals of treating acute asthma are to:
• prevent worsening
• relieve airway obstruction (rapidly improves symptoms)
• treat hypoxia
• restore lung function to normal or previous best
• prevent relapse.
5.3.1 Bronchodilators
There are several classes of bronchodilators for acute asthma, each 
with a different mode of action and used sequentially depending on 
the response to treatment. They are presented in order of importance 
with a view to a stepwise approach to treatment.
5.3.1.1 β2-agonists
Short-acting inhaled β2-agonists (SABAs), e.g. salbutamol and 
fenoterol, are the cornerstone of bronchodilator treatment for acute 
asthma exacerbations[1,11,12] (evidence A). They act by stimulating 
β2 receptors in the airways. When the patient responds well to 
SABAs (usually 2 or 3 doses given by nebulisation or metered dose 
inhalation) there is no need for any other bronchodilator treatment 
for acute asthma.[1] The following are the key properties of SABAs:
• They are administered by inhalation, most commonly by 
nebulisation in acute asthma.
• They rapidly improve airway obstruction.
• Recent exacerbation




NO IMPROVEMENT NO IMPROVEMENT
IMPROVEMENT
Transfer to high care/
ICU with ventilation
facility
FEATURES OF HIGH RISK
• Previous near-fatal asthma
• Recent course of
corticosteroids 
• IN EXTREMIS − silent chest,
         cannot talk, drowsy, confused,
bradycardia, hypercapnia
• Continuous nebulisation with salbutamol
   and ipratropium bromide 
• Magnesium sulphate 1 - 2 g IV
• Hydrocortisone IV 100 - 200 mg 6-hourly
• Oxygen, IV uids, calories
• Repeat arterial blood gas
• Continuous review for complications
• Nebulise with salbutamol
  every 20 minutes or 
  continuously
• Add ipratropium bromide
  0.5 mg UDV to nebs
• IV line − uids, calories
• Oxygen
• Measure arterial blood gas if
  facility available
• Antibiotics only if signs of 
  infection
• Continuous review for
  complications
• Continuous nebulisation with
   salbutamol and ipratropium bromide
• IV aminophylline – loading dose
  5 mg/kg over 30 minutes
  (half if on oral
  theophyllines), maintenance
  infusion of 0.5 mg/kg/h
• Continue IV hydrocortisone 6-hourly
• May repeat IV MgSO4 in 12 hours
• Continuous review for
  complications such as
  pneumothorax
• Oxygen, IV uids, calories
• Consider salbutamol IV infusion
• Improvement in symptoms and signs; pulse <120, resp.
   rate <20, O2 saturation >92% on room air
• Arterial blood gas normalised on room air: PaO2 >8 kPa
  (60 mmHg); PaCo2 <6 kPa (45 mmHg)
• Able to converse in full sentences
• PEF >60% predicted or personal best
• Prepare discharge plan; prednisone 20 - 40 mg/day for
  7 - 14 days (don’t taper); commence controller
  medications 
• BASELINE ASSESSMENT − must not delay institution of treatment
MANAGEMENT
• Nebulise with salbutamol (5 mg UDV) - preferably O2-driven nebuliser
  or 20 puffs salbutamol MDI with large - volume spacer
• Oral prednisone 0.5 mg/kg stat or hydrocortisone 100 - 200 mg (or
   equivalent) IV immediately if severe or unable to swallow
• Monitor O2 saturation if facility available
• Monitor peak flow
BASELINE ASSESSMENT:
• Clinical − pulse, resp. rate
• Measure peak expiratory
  flow, O2 saturation, and 
  arterial blood gases if indicated
• Exclude infection,
  pneumothorax
• Exclude other causes of acute
  airway obstruction
• Chest X-ray only if necessary
• Severe if cannot talk in more 
  than single words, resp rate
  >30/min, pulse 120/min,
  hypoxic and/or hypercapnic,
  peak flow <100 l/min
Fig. 1. Algorithm for the management of acute asthma.
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• They may be repeated as frequently as necessary depending on 
the patient’s response: clinical improvement and improvement 
in peak flow to >60% predicted or >60% of previous best. 
Some experts propose 75%. β2-agonists may be administered 
continuously (every 20 minutes) in acute asthma.[13,14]
• In severe acute asthma, it is recommended that whenever 
possible they should be administered using an oxygen-driven 
nebuliser.
• They are relatively safe even in high doses when administered 
by nebulisation.
• They may be given by intravenous infusion in exceptional 
circumstances when nebulisation is not possible or is considered 
unreliable.[15]
How to administer?
SABAs are administered repeatedly as the best way of achieving 
rapid reversal of airflow obstruction (Table 4)[11,12] (evidence A). 
If the attack is severe or life-threatening, delivery via an oxygen-
driven nebuliser is mandatory. In mild to moderate exacerbations 
a metered dose inhaler (MDI) together with a large-volume spacer 
(LVS) produces at least an equivalent improvement in lung function 
and is more cost-effective.[16] If using an MDI plus an LVS, put 2 
puffs (100 µg/puff) into the LVS and advise the patient to take 
several deep breaths from the spacer, repeating the procedure for up 
to 20 puffs over 20 minutes for 1 hour. For nebulisation administer 
5 mg salbutamol or 1 mg fenoterol, available in premixed unit 
dose vials (UDVs), initially. If a rapid response is not obtained, 
repeat the nebulisation every 20 minutes (continuously) for 1 hour. 
After the first hour, the frequency will depend on the severity of 
the attack and the response to initial treatment. No additional 
bronchodilator medication is necessary if the SABA produces a 
complete response (PEF returns to >60% of predicted or personal 
best) and the response is sustained for several hours. Consider 
continuous nebulisation (3 UDVs per hour) in patients with severe 
acute asthma (PEF or FEV1 <50% of previous best or predicted) 
and those poorly responsive to initial intermittent β2-agonist 
therapy[13,14] (evidence A).
Intravenous salbutamol is rarely used. It is given as an initial 
dose of 0.5 mg intravenously slowly, followed by a maintenance 
dose of 3 - 20 µg/min (5 mg diluted in 500 ml dextrose water or 
normal saline). It should be continued until there is sustained 
improvement (ideally <24 hours). Serum potassium and lactate 
should be monitored.
Table 2. Severity of acute asthma (exacerbations)*
Mild Moderate Severe Respiratory arrest imminent
Breathless Walking Talking At rest
Can lie down Prefer sitting Hunched forward
Talks in Sentences Phrases Words
Alertness May be agitated Usually agitated Usually agitated Drowsy or confused
Respiratory rate Increased Increased Often >30/min Silent chest
Accessory muscles and 
suprasternal retractions
Usually not Usually Usually Paradoxical thoraco-abdominal 
movement
Wheeze Moderate Loud Usually loud Absence of wheeze
Pulse rate (/min) <100 100 - 120 >120 Bradycardia
Pulsus paradoxus Absent <10 mmHg May be present 
<20 mmHg
20 - 40 mmHg Absence implies respiratory 
muscle fatigue
PEF after initial 
bronchodilator, 
% predicted or 
% personal best
>80% Approx. 60 - 80% <60% of predicted or personal 
best (<100 l/min adults)
OR
Response lasts <2 hours
PaO2 (breathing room air) Normal >60 mmHg (8 kPa) <60 mmHg (8 kPa)
Test not usually necessary cyanosis
AND/OR
PaCO2 <45 mmHg (6 kPa) <45 mmHg (6 kPa) >45 mmHg (6 kPa)
SaO2 % (on room air)
 >95% 91 - 95% <90%
*The presence of several parameters, but not necessarily all, indicates the general classification of the exacerbation.
PaO2 = arterial blood oxygen partial pressure; PaCO2 = arterial blood carbon dioxide partial pressure; SaO2% = arterial oxygen saturation.
Table 3. High-risk patients
Current use of or recent withdrawal from systemic corticosteroids
Recent emergency care and/or hospitalisation for asthma
Frequent emergency care attendance
Previous resuscitation and/or intensive care unit admission for severe 
attack
Previous sudden severe attack/s with few or no warning features 
despite regular treatment (so-called ‘brittle asthma’)
Recent over-reliance on and excessive use of β2-agonists
History of non-adherence with asthma medication
History of psychosocial problems
GUIDELINES
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5.3.1.2 Anticholinergics
Inhaled ipratropium bromide is the only anticholinergic agent 
for the treatment of acute asthma. It achieves bronchodilation by 
a vagal pathway through inhibition of muscarinic receptors. Its 
bronchodilator effect in asthma is inferior to that of SABAs. The key 
properties of ipratropium bromide are:
• It is administered by inhalation only – most commonly by 
nebulisation or with an MDI with an LVS.
• There is no evidence that it provides significant additional 
bronchodilator effect to optimal doses of SABAs in mild to 
moderate acute asthma. It is therefore reserved as a second-line 
bronchodilator treatment for severe acute asthma.
• Combination with a SABA produces better bronchodilation than 
either drug alone[17,18] (evidence B) and is associated with lower 
hospitalisation rates in severe acute asthma[17-19] (evidence A). It is 
usually added to SABA nebulisation solution when there is poor or 
inadequate response to repeated doses of inhaled SABAs.
How to administer?
Ipratropium bromide may be administered in combination with a 
SABA every 20 minutes via a nebuliser at a dose of 0.5 mg in UDVs. 
It may also be administered via an MDI and LVS (20 µg/puff, up to 
20 puffs).
5.3.1.3 Magnesium sulphate
Magnesium sulphate has recently been demonstrated to have 
bronchodilator effects and is of value (reducing hospital admission) 
in severe acute asthma when other bronchodilators fail[20-22] (evidence 
A). It probably works by inhibiting smooth-muscle contraction, 
decreasing histamine release from mast cells, and inhibiting 
acetylcholine release. The properties of magnesium sulphate are:
• It is mainly used intravenously (can be used by nebulisation with 
SABAs but with much less benefit[22-24]).
• It is not recommended routinely in acute asthma, but is of value 
in severe acute asthma (patients with FEV1 <25%) and those not 
responsive to other bronchodilators.
• It is generally safe, but may be associated with side-effects of 
flushing, sweating, hypotension, nausea, muscle weakness and 
central nervous system depression.
How to administer?
Intravenous magnesium sulphate may be given as a 1 - 2 g infusion 
over 20 minutes. It should be given as a single-dose infusion and may 
be repeated once, but not sooner than 12 hours.
Nebulised magnesium sulphate should be administered at a dose 
of 135 - 1 150 mg together with a SABA, but this is far less effective 
than intravenous administration.[23,24]
5.3.1.4 Theophylline
Intravenous aminophylline is the only theophylline recommended 
in acute asthma. It is a theophylline with ethylenediamine to render 
it water-soluble. It is thought to act by phosphodiesterase inhibition 
and non-selective adenosine receptor antagonism. Selective 
phosphodiesterase inhibitors such as roflumilast are not registered 
for use in acute asthma. The properties of aminophylline are:
• It has a very narrow therapeutic range, and toxicity is common 
(cardiac arrhythmias, nausea and vomiting, convulsions, 
hypotension and coma).[25]
• It is not routinely given in acute asthma, as no synergism has been 
demonstrated. Only recommended when there is no response to 
SABAs, ipratropium bromide and magnesium sulphate (i.e. severe 
refractory asthma).
How to administer?
A loading dose of 5 mg/kg is infused over 30 minutes (withhold 
or give only half the dose to patients already on oral theophylline), 
followed by a maintenance infusion of 0.5 mg/kg/h (approximately 
1 000 mg/24 h). This should be increased by one-third (0.9 mg/
kg/h) in smokers and patients taking phenytoin and decreased by 
one-third in the elderly and those with congestive cardiac failure 
or liver disease, or taking a macrolide, ciprofloxacin or cimetidine. 
Blood levels should be monitored daily and the dose adjusted 
accordingly.
5.3.1.5 Others
Adrenaline has been replaced by the β2-agonists and is rarely 
indicated for acute asthma attacks. It may, however, be used if 
no intravenous access is immediately available and the patient is 
moribund. Subcutaneous adrenaline (0.3 ml of 1/1 000 solution, 
repeated every 20 minutes if no response) has been successful 
and side-effects are not significant even when given intravenously 
under emergency circumstances. It has also been administered 
via an endotracheal tube if a patient is unable to take inhaled 
medication and/or there is no intravenous access.[1] It may also be 
used if there is associated anaphylaxis or angio-oedema. Special 
care must be taken in the elderly and those with or at risk of 
cardiovascular disease.
5.3.2 Glucocorticosteroids
Glucocorticosteroids are recommended routinely for the treatment 
of acute asthma (evidence A).[26,27] They are the most important anti-
inflammatory agents in asthma. The key properties of CS are:
• They prevent relapse.[26,27]
• Onset of action is within hours of administration, and the 
first dose should be given orally or intravenously immediately 
treatment for acute asthma is commenced.
• Oral CS are usually as effective and work as quickly as those given 
intravenously, and are preferred because they are cheaper and less 
invasive.[28,29]
• CS need to be continued for 7 - 14 days.[30] 
• CS have been shown to be effective when administered by MDI or 
nebulisation in acute asthma,[31,32] but the inhaled route is not cost-
effective or as reliable as systemic administration in acute asthma. 
There is insufficient evidence that the inhaled route can replace 
systemic CS in acute asthma.[33,34]
• They result in resolution of the airway inflammation that 
contributes significantly to the airway obstruction in acute asthma 
and is not reversed with bronchodilators such as β2-agonists, 
anticholinergics, magnesium sulphate and theophylline.
How to administer?
CS are usually given in the form of oral prednisone (0.5 - 1 mg/kg 
or equivalent per day, usually 30 - 50 mg daily) in all patients with 
acute asthma attacks [26,27] (evidence A) and continued for 7 - 14 
days.[30] There is no advantage in using a higher dose [26,27] (evidence 
B) or in tapering the dose when administered for this duration[35] 
(evidence B). Intravenous CS (hydrocortisone 100 - 200 mg or 
equivalent, 6-hourly) can be used if the patient is vomiting or unable 
to take oral medication. Highly potent CS such as dexamethasone 
and betamethasone are not recommended in acute asthma.
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Standard-dose inhaled CS should be started during the admission 
and continued on discharge as part of chronic therapy[31-34,36-38] 
(evidence A).
5.3.3 Oxygen
Supplemental oxygen must be administered whenever possible in 
patients with moderate to severe acute asthma. Also, nebulised 
bronchodilators should whenever possible be delivered by oxygen-
driven nebulisers. Most patients with moderate to severe acute 
asthma have hypoxia that is readily corrected by supplemental 
oxygen.
How to administer?
Oxygen is generally administered by facemask and response monitored 
with pulse oximetry to maintain an O2 saturation over 92%[1,6,39] 
(evidence C). Lack of pulse oximetry should not prevent oxygen 
being administered. There is usually no need to administer more than 
40% oxygen. The flow rates are determined by the recommendations 
on the specific facemasks. If inhaled bronchodilator therapy is given 
by nebulisers, they should preferably be driven by oxygen at a flow 
rate of at least 6 l/min to prevent hypoxaemia[6,40] (evidence A).
5.3.4 Miscellaneous treatments
Antibiotics are not routinely indicated in acute asthma and should only 
be given if there is definite evidence of infection such as fever, purulent 
sputum and clinical and/or radiological signs of pneumonia. [41,42] Note 
that yellowish sputum is frequent in acute asthma and is due to the high 
eosinophil content and not a sign of infection on its own.
Intravenous fluids are administered in acute severe asthma 
based on the clinical setting, taking into account maintenance and 
replacement requirements and the need for calorie intake in patients 
unable to take oral fluids. There are no formal studies of routine fluid 
administration in acute asthma.
Heliox is a mixture of helium and oxygen. It has the advantage 
of reducing airway resistance and has been used in desperate 
circumstances in non-responsive severe acute asthma.[43-45] It is not 
available in most centres.
5.3.5 Treatments for which there is no evidence of benefit and/or 
that should be avoided
Leukotriene modifiers are not currently recommended in acute 
asthma.[1,46]
Antihistamines have no role in acute asthma.
Mucolytics, given either systemically or by nebulisation, are 
contraindicated as they may worsen cough and bronchospasm and 
only serve to complicate the treatment regimen.
Sedatives should be strictly avoided during asthma attacks because 
of their respiratory depressant effect. Their use in non-intubated 
patients has been associated with asthma deaths.[42,47,48]
Physiotherapy may provoke bronchospasm and worsen the attack. 
It is only indicated if there is lobar collapse that persists despite initial 
bronchodilator and CS therapy.[42]
5.3.6 Stepwise treatment of acute asthma
The stepwise treatment of acute asthma is set out in Table 4.
5.4 Assessment of response to treatment
Measurements of pulse rate, respiratory rate, PEF or FEV1 and arterial 
oxygen saturation should be made at 15 - 30-minute intervals until 
a clear response to treatment is achieved.[3-5,42,49] Measurement of the 
change in PEF in response to initial therapy is one of the best ways 
to assess response to treatment for acute asthma.[1,42,49] Early response 
to treatment (PEF at 30 minutes) is the most important predictor of 
outcome and need for hospitalisation.[42,49] Criteria for endotracheal 
intubation and/or intensive care unit (ICU) admission are listed in 
Table 5. ICU management of acute asthma is described below. Once 
a satisfactory response is obtained the patient may:
• be discharged on a course of oral prednisone for 7 - 14 days 
together with controller medication
• continue to receive bronchodilator treatment in the emergency 
room, ward, high-care unit or ICU at a frequency of 4 - 
8-hourly based on the attending physician’s discretion. Ongoing 
monitoring of baseline parameters such as clinical status, PEF, 
SpO2, arterial blood gas, etc. is at the attending physician’s 
discretion.
Table 4. Stepwise treatment of acute asthma
A. First line Oxygen: by 40% facemask or nasal cannulas to keep saturation >92%
SABAs: via nebuliser (5 mg salbutamol or 1 mg fenoterol in premixed UDVs) every 20 minutes until a satisfactory response; 
or via MDI plus LVS (10 - 20 puffs (100 µg/puff) over 20 minutes, taking several deep breaths from spacer after every 2 puffs) 
Systemic corticosteroids: prednisone 0.5 - 1 mg/kg orally stat and daily; or hydrocortisone (or equivalent) 100 - 200 mg 
intravenously 6-hourly in severe acute asthma or if unable to swallow or vomiting
These treatments are usually administered concurrently to achieve the most rapid resolution of the attack and prevention of 
relapse
B. Second line Ipratropium bromide: 4-hourly via nebuliser (0.5 mg in premixed UDVs, usually with a SABA) every 20 minutes until a 
satisfactory response; or via MDI plus LVS (up to 20 puffs (20 µg/puff) over 20 minutes, taking several deep breaths from 
spacer after every 2 puffs)
C. Third line Intravenous magnesium sulphate: 1 - 2 g infusion over 20 minutes
Intravenous aminophylline: loading dose of 5 mg/kg infusion over 30 minutes (administer half the dose if on maintenance 
theophyllines), then maintenance infusion of 0.5 mg/kg/h
D. Fourth line Intravenous salbutamol: 0.25 mg IV slowly, then maintenance infusion of 3 - 20 µg/min
SABAs = short-acting inhaled β2-agonists; UDVs = unit dose vials; MDI = metered dose inhaler; LVS = large-volume spacer.
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5.5 Mechanical ventilation
• Intubation should be performed with a large-diameter tube by the 
most experienced person available. The induction agent is a matter of 
personal preference. Benzodiazepines cause respiratory depression, 
so the initial attempt must be rapidly successful. Etomidate (0.2 - 
0.4 mg/kg), propofol (2 - 2.5 mg/ kg) and ketamine (1 - 2 mg/kg) 
are other options. The latter has sedative, analgesic and anaesthetic 
properties without respiratory depression, but increases bronchial 
secretions and causes hallucinations. Succinylcholine remains the 
agent of choice for acute paralysis despite histamine release.[50] 
Volume modes ensure delivery of a tidal volume (TV) that exceeds 
physiological dead space (usually 5 - 6 ml/kg ideal body weight or 
250 - 300 ml).[51]
• Set the peak pressure alarm such that the desired volume is actually 
delivered. The pressure required to deliver an adequate TV may 
be quite high when airflow resistance is very high. Considerable 
expertise is required to manage ventilation in these patients.
• Auto-PEEP (positive end-expiratory pressure). Auto-PEEP causes 
hyperinflation and haemodynamic compromise and should be 
minimised. Auto-PEEP is influenced by respiratory rate, TV, and 
the inspiratory-to-expiratory time ratio and inspiratory flow rates. 
Ventilator graphics make the monitoring of PEEP much simpler.[52]
• Start with a respiratory rate of 8 - 12 breaths per minute with no or 
minimal external PEEP.
• Permissive hypercapnia, a higher CO2 than normal, is acceptable 
provided the pH is >7.2. If the pH is less than this, increase the 
respiratory rate cautiously as this may increase auto-PEEP.
• Short-duration paralysis may sometimes be necessary. Non-
depolarising agents such as vecuronium bromide, rocuronium 
bromide, cisatracurium besilate and pancuronium bromide may 
all be used and do not induce bronchospasm. Atracurium besilate 
and mivacurium chloride cause dose-dependent histamine release, 
but it is not certain whether this causes clinical deterioration. 
Stop paralysis as soon as possible, as the combination of steroid 
and neuromuscular blocking agents is particularly likely to cause 
critical illness myopathy.[53]
• When the patient improves, convert to pressure support modes. 
A trial of external PEEP is warranted as this may decrease work 
in spontaneously breathing patients.[54] Non-invasive ventilation 
remains controversial and is not routinely recommended.[55]
Criteria for endotracheal intubation/ICU admission are listed in 
Table 5, and suggested criteria for discharge from the emergency unit 
in Table 6.[49,56-59] If the pretreatment FEV1 or PEF is <25% predicted or 
personal best, or the post-treatment FEV1 or PEF <40% predicted or 
personal best, admission is usually required.[1,59]
Once admitted for poor response, the optimal duration of 
hospital stay is unclear. There is often major bed pressure to 
discharge patients too early, but this increases the risk of early 
relapse. Readmission may occur in the next 2 - 3 months,[57] 
particularly if the diurnal variation in PEF is >20%, and a course 
of oral CS and optimisation of long-term controller treatment are 
essential to reduce relapse.[58]
5.6 Prevention of relapses
The factors that precipitated the attack should be identified and 
attempts made to avoid them.[60-63]
5.7 Discharge plan
• Provide a 7 - 14-day course of oral CS (20 - 40 mg daily of 
prednisone or equivalent). No tapering required if used for this 
duration.
• Instruct the patient to use their inhaled bronchodilator (SABA) 
as required for both symptomatic and objective improvement 
(PEF if available) until they are stable and return to their 
baseline.
• Review the patient’s use of controller therapy during the 
exacerbation. Patients should commence or continue inhaled 
CS (frequently in the form of a combination inhaler with 
long-acting β2-agonists). If the patient was already on 
inhaled CS, careful attention should be paid to reviewing 
the dose. Consider providing a short course of oral CS to be 
taken in the event of subsequent exacerbations for frequent 
exacerbators.
• The patient’s inhaler technique and use of a peak flow meter to 
monitor therapy at home should be reviewed.
• A follow-up appointment with the patient’s usual primary care 
provider or an asthma specialist should be made within 2 weeks 
of discharge to ensure that treatment is continued to achieve 
control. Ideally, patients discharged from the emergency unit 
should be referred to specialist care as they do better than those 
returned to routine care.[64]
• The patient’s response to the attack should be evaluated. A 
written asthma action plan should be reviewed or provided. 
Hospitalised patients are more receptive to information and 
advice about their illness.[63] Healthcare providers should take 
the opportunity to review patient understanding of the causes of 
asthma attacks, trigger avoidance (including smoking cessation), 
the purpose and correct use of treatment, and the action to take 
in response to worsening symptoms or peak flow values[60-63]
(evidence A).
Table 5. Criteria for endotracheal intubation/ICU admission






f. Rising PaCO2 
g. Persistent acidosis
h. Respiratory arrest
2. Poor response to initial therapy at clinic/hospital (PEF deteriorates)
PaCO2 = arterial blood carbon dioxide partial pressure; PEF = peak expiratory flow.
Table 6. Criteria for discharge from the emergency unit
1.  Adequate response to initial therapy within 1 - 2 hours (as evidenced 
by pulse, respiratory rate, wheeze/breath sounds, oxygen saturation)
2. PEF improves to >60% predicted (some experts propose 75%)
3. No prolonged symptoms before current emergency unit visit
4. No recurrence after recent exacerbation
5. Absence of high-risk factors 
6.  Good social factors (adequate access to medical care, medicines 
and transport)
PEF = peak expiratory flow.
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Fig. 2. The mini-Wright peak flow meter.
Appendix I. How to measure peak 
expiratory flow (PEF)
As airways narrow, the PEF rate falls. The PEF is usually measured 
using the mini-Wright peak flow meter (Fig. 2). Careful instruction 
is required to measure PEF reliably because its measurement is 
effort-dependent.[1] The maximum rate of flow of air that the 
patient can forcibly exhale starting from full inhalation, expressed 
in litres per minute, is measured. It should be explained in simple 
terms (‘take a deep breath in, and then blow out as hard and fast 
as possible into the meter, like blowing out the candles on a cake’). 
However, it is much easier and more effective to show a patient 
how to use a peak flow meter than to explain it to them in words 
only. PEF should be recorded as the best of three forced expiratory 
blows from total lung capacity in a standing or sitting position, with 
a maximum pause of 2 seconds before blowing.[2] The subject does 
not have to exhale completely.
PEF expressed as a percentage of the patient’s previous best 
value is most useful clinically, but in the absence of a known 
previous best value, it should be expressed as a percentage of 
predicted.[1,2] PEF depends on the patient’s age, sex and height. 
The normal reference values sourced from the Nunn and Gregg 
nomogram are recommended for the calculation of ‘percentage 
predicted’ PEF values[2,3] (Fig. 3).
Normal values for peak expiratory ow (PEF)
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Fig. 3. The Nunn and Gregg nomogram for determining predicted peak 
expiratory flow rates in adolescents and adults.
